



P. Edward Purdue, Tania N. Crotti, Zhenxin Shen, Jennifer Swantek, Jun Li, Jonathan Hill, 
Adedayo Hanidu, Janice Dimock, Gerald Nabozny, Steven R. Goldring, Kevin P. McHugh 
Comprehensive profiling analysis of actively resorbing osteoclasts identifies critical 
signaling pathways regulated by bone substrate 
Scientific Reports, 2014; 4:7595-1-7595-11 
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 
International License. The images or other third party material in this article are included in the 
article's Creative Commons license, unless indicated otherwise in the credit line; if the material is 
not included under the Creative Commons license, users will need to obtain permission from the 
































8 September, 2015 
Comprehensive profiling analysis of
actively resorbing osteoclasts identifies
critical signaling pathways regulated by
bone substrate
P. Edward Purdue1, Tania N. Crotti2,3, Zhenxin Shen3, Jennifer Swantek4, Jun Li4, Jonathan Hill4,
Adedayo Hanidu4, Janice Dimock4, Gerald Nabozny4, Steven R. Goldring1 & Kevin P. McHugh5
1Hospital for Special Surgery, New York, NY 10021, 2School of Medical Sciences, The University of Adelaide, Adelaide 5005,
Australia, 3Beth Israel Deaconess Medical Center, Boston, MA 02215, 4Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT,
06877, 5University of Florida College of Dentistry, Gainesville, FL, 32610.
As the only cells capable of efficiently resorbing bone, osteoclasts are central mediators of both normal bone
remodeling and pathologies associates with excessive bone resorption. However, despite the clear evidence
of interplay between osteoclasts and the bone surface in vivo, the role of the bone substrate in regulating
osteoclast differentiation and activation at a molecular level has not been fully defined. Here, we present the
first comprehensive expression profiles of osteoclasts differentiated on authentic resorbable bone
substrates. This analysis has identified numerous critical pathways coordinately regulated by
osteoclastogenic cytokines and bone substrate, including the transition fromproliferation to differentiation,
and sphingosine-1-phosphate signaling. Whilst, as expected, much of this program is dependent upon
integrin beta 3, the pre-eminent mediator of osteoclast-bone interaction, a surprisingly significant portion
of the bone substrate regulated expression signature is independent of this receptor. Together, these
findings identify an important hitherto underappreciated role for bone substrate in osteoclastogenesis.
T
he function of osteoclasts is to resorb bone, and they represent themajor cell type responsible for this critical
step in homeostatic bone remodeling and in pathological bone loss disorders1,2. Recent years have seen
remarkable advances in the understanding of the signaling pathways required for osteoclast formation and
activation, and of how these processes are regulated by the essential osteoclastogenic cytokines Receptor activator
of nuclear factor kappa-B ligand (RANKL) and Macrophage colony-stimulating factor (M-CSF)3–5. RANKL and
M-CSF are necessary and sufficient for the in vitro generation frommyeloid precursor cells ofmultinucleated cells
that bear the hallmarks of osteoclasts. The ability to generate osteoclast-like cells in vitro with high efficiency has
been instrumental in identifying at a molecular level numerous key factors involved in this process. However,
these studies have almost without exception been limited to cells differentiated on tissue culture plastic or glass
surfaces, and have therefore failed to address the critical role played by bone substrate in osteoclast differentiation,
polarization, and activation6–11. Since fully functional osteoclasts exist exclusively upon bone surfaces in vivo, the
paucity of information regarding how bone substrate regulates these cells represents a significant and important
gap in our knowledge of osteoclast biology.
Integrin beta 3 (itgb3) is a critical mediator of the interaction of differentiating osteoclasts with bone sub-
strate12,13. Itgb3 is highly induced in differentiating and mature osteoclasts, and forms a complex with integrin
alpha v on the surface of osteoclasts that binds to extracellular matrix components present in bone and thus plays
an important role in osteoclast-bone interactions. Mice lacking itgb3 generate osteoclasts that are unable to
properly polarize upon bone substrates, and thus exhibit a defect in bone resorption, accentuating the critical role
of itgb3 mediated adhesion to bone in osteoclast differentiation and activation12. A critical role for itgb3 has also
been demonstrated in mouse models of ovariectomy-induced osteoporosis14 and cancer metastasis to bone15.
In this study we have provided the first comprehensive gene expression profiling of mouse bone marrow
macrophage (BMM)-derived osteoclasts on bone and hydroxyapatite (HA) substrates. Using time course analysis
of osteoclasts generated on plastic, HA and bone, we have identified a unique cluster of osteoclast genes specif-
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itgb3 knockout (Itgb3 2/2) cells differentiated on bone to delineate
the role of itgb3 in activation of bone-dependent osteoclast genetic
programs. These analyses identified the pathway responsible for
synthesis, transport and signaling by the lipid mediator sphingo-
sine-1-phosphate (S-1-P) as a prototypical member of the bone-
and itgb3-regulated genes and additional studies confirmed the
critical role of this pathway in regulating the differentiation and
activation of osteoclasts. Furthermore, we have demonstrated that
bone substrate regulates the switch from cell cycle progression to
differentiation and activation at late stages of osteoclastogenesis.
Results
Expression profiling of mouse osteoclasts differentiated on bone
related substrates. In order to determine the role of bone matrix in
osteoclast formation and function, we differentiatedmouse BMMs to
osteoclasts on authentic devitalized mouse bone, or on the non-bone
substrates HA or tissue culture plastic. After 5 days of culture with
RANKL, osteoclasts on mouse calvarial bone discs displayed actin
rings characteristic of polarized and actively resorbing osteoclasts
while osteoclast-like cells on plastic displayed characteristic
podosome bands (Fig. 1a and 1b respectively)16.
As detailed in Methods, quadruplicate cultures prepared from
individual animals were processed for RNA extraction at early (day
1), intermediate (day 3) and terminal (day 5) stages of RANKL-
induced osteoclastogenesis. BMMs were cultured for equivalent
times on mouse bone, HA and tissue culture plastic, in the presence
of M-CSF, but not RANKL as a control.
Following confirmation of RNA quality by Biacore analysis and
analysis of results from hybridization to test chips, genome-wide
expression profiles were determined on Affymetrix Gene Chips
(Mouse Genome 430 2.0) for each of the 4 replicates with and
without RANKL, on each substrate and over 3 time points.
Hierarchal cluster analysis identified gene clusters specifically
regulated by RANKL (independent of substrate) and by sub-
strate-dependence (Fig. 1c). In accordance with previous studies,
this analysis revealed that RANKL, independent of substrate,
induced expression of subsets of genes with known involvement
in osteoclast biology and function, including: TRAP, cathepsin-k,
calcitonin receptor, itgb3, OSCAR, and NFATc1. The RANKL-
induced expression profiles transitioned substantially during the
time-course of the analysis, as the macrophage precursors differ-
entiated through the stages of pre-osteoclast, committed osteoclast
precursors, and differentiated, bone-resorbing osteoclast. As deli-
neated in Fig. 1d, the number of RANKL regulated genes
increased substantially between days 1–3, when pre-osteoclasts
are differentiating into immature osteoclasts, and increased more
moderately during the later stages of differentiation of fully
mature osteoclasts (days 3–5).
Substrate induction of RANKL induced genes. Notably, we also
observed that the well-established pattern of RANKL-induced
osteoclast gene expression could be significantly reprogrammed by
the nature of the growth substrate. At each time point, a subset of the
RANKL-induced genes was further regulated by the presence of
bone. Osteoclasts differentiated on HA substrate (not shown)
tended towards an expression profile intermediate to those seen on
plastic and bone. As shown in Fig. 1d, the numbers of RANKL-
induced genes that were super-regulated both positively and
negatively by bone substrate, were considerably higher on day 5,
when the osteoclasts are undergoing terminal differentiation and
activation, than at earlier time points. Interestingly, there was little
overlap in the gene sets super-regulated by bone at the different time-
points (Fig. 1e), suggesting that the bone regulated expression
program is linear and highly dynamic, and dependent upon the
differentiation state of the cell.
Specific subsets of bone-regulated osteoclast genes are dependent
upon itgb3, whereas other genes are itgb3-independent. Since
itgb3 has been shown to play a critical role in regulating the
morphological and functional activity of osteoclasts12, we next
assessed the contribution of itgb3 signaling to the identified bone-
dependent gene expression profile. Consistent with its role in
interaction with bone substrate, expression of itgb3 was induced by
RANKL, and super-induced by bone substrate during late stages of
osteoclast differentiation (Fig. 2a). To directly address the role of
itgb3 in bone regulated osteoclastogenesis, BMMs from three
individual wild-type and three individual Itgb3 knockout mice
(Itgb3 2/2) were isolated and subjected to osteoclastogenesis (in
the presence of M-CSF and RANKL) on tissue culture plastic and
devitalized mouse calvarial bone slices, as described above. Actin
ring staining by Rhodamine Phalloidin confirmed that although
itgb3 2/2 osteoclasts retain the ability to attach to the bone
surface, they fail to form actin rings, consistent with the defective
resorption activity of osteoclasts lacking itgb3 (Fig. 2b)12,17–22.
Consistent with the pre-eminent role of itgb3 in osteoclastogen-
esis, microarray analysis and hierarchical clustering (Fig. 2c) revealed
that absence of this integrin resulted in significant changes in the
pattern of gene expression during RANKL-induced differentiation of
BMMs. Significantly, cluster analysis identified not only sets of bone-
regulated genes that were dependent upon the presence of itgb3, but a
novel cluster of genes whose induction by bone substrate was un-
affected or enhanced by the absence of itgb3. The identification of
bone-regulated, itgb3-independent genes is notable since it implies
the existence of multiple bone-derived signaling pathways for regu-
lation of gene expression in differentiating osteoclasts.
Independently qPCR analysis was utilized to confirm the ability of
bone to up-regulate specific osteoclast genes in either an itgb3-inde-
pendent (e.g. AnxA8) or itgb3-dependent (e.g. UCHL1 and FKBP9)
manner (Table 1).
Taken together, the results from expression profiling show that
multiple mechanisms including cytokine signaling (RANKL), integ-
rin-based attachment to substrate (itgb3) and the nature of the sub-
strate itself (bone) drive gene expression and cell differentiation of
osteoclasts. Moreover, these different regulators of osteoclast differ-
entiation operate in overlapping fashion to coordinate the complex
events that constitute osteoclast formation and activation.
Pathway analysis and functional classification. Several approaches
were taken towards identification of the signaling pathways
coordinately regulated by bone substrate and/or itgb3 during
RANKL-induced osteoclastogenesis. Ingenuity Pathway Analysis
(IPA) identified several bone regulated functional categories,
including regulation of cell survival and proliferation (Table 2).
Gene Set Enrichment Analysis (GSEA) was further used as a
means to look for pathways that were differentially regulated by
these stimuli. This confirmed that bone substrate profoundly
influences osteoclast proliferation and differentiation, as
highlighted by a bone substrate-induced repression of expression
of genes associated with cell cycle progression and cell division
(Fig. 3a).
As highlighted for representative genes cdc7 and cyclin b1
(Fig. 3b), genes within this pathway show amodest decrease between
days 3–5 on plastic, but a much more prominent loss of expression
during the same period of culture on bone. The repression of cell
cycle genes in osteoclast differentiation on bone indicates the induc-
tion of a transcriptional program that arrests osteoclast proliferation
during the late stages of osteoclast differentiation. Absence of itgb3
had a remarkably similar impact upon this pathway as absence of
bone (i.e. growth on plastic), with numerous genes associated with
cell cycle progression being elevated in day 5 osteoclasts in the
absence of itgb3 (Fig. 3a). This strongly reaffirms the importance
of itgb3 for osteoclast development, and indicates that the bone
www.nature.com/scientificreports
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substrate mediated decline in cell cycle progression is a highly itgb3-
dependent process. Interestingly, macrophages cultured in the
absence of RANKL also show a decrease in expression of cdc7 and
Cyclin B1 between 3 and 5 days in culture (2RL in Fig. 3b) as the cells
reach confluency. However, unlike in osteoclasts, this effect is not
modulated by bone substrate, suggesting that the bone substrate-
mediated switch from proliferation to activation is specific for
RANKL-induced osteoclasts and not a common feature of myeloid
cells.
Regulation of the S-1-P pathway during osteoclastogenesis on
bone substrate. GSEA analysis identified several additional
pathways regulated by bone and itgb3. Prominent among these
was the S-1-P pathway (termed the EDG1 pathway in this analysis,
Figure 1 | Bone substrate regulates gene expression in differentiating murine osteoclasts. (a) Phalloidin stain showing distinctive actin morphology of
wild type BMM-derived osteoclasts differentiated on bone. (b) Phalloidin stain showing distinctive actin morphology of wild type BMM-derived
osteoclasts differentiated on plastic. (c) Hierarchical clustering heat map of mouse BMM-derived osteoclast expression profiles regulated by RANKL,
stage of differentiation and culture substrate. (d) Total numbers of RANKL-induced genes that are further regulated, or unaffected, by bone substrate. (e)
Venn diagram of the overlap between genes regulated .23 by bone on days 1, 3 and 5.
www.nature.com/scientificreports
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with EDG1 being a cell surface receptor for S-1-P), which includes
the protein mediators involved in the generation, transport and
signaling of S-1-P. Based upon this observation, and the fact that a
number of reports have suggested an important role for S-1-P and
EDG signaling in osteoclast biology23–28, we investigated this pathway
in greater detail.
GSEA analysis revealed that the S-1-P pathway was significantly
regulated independently by RANKL, bone substrate and itgb3
Figure 2 | Itgb3 signaling mediates the effects of bone substrate on osteoclastogenesis. (a) Detailed microarray analysis of itgb3 expression in cells
cultured for 1, 3 and 5 days on plastic or calvaria (bone), in the presence (1RL) or absence (2RL) of RANKL. (b) Phalloidin stain showing distinctive
actin morphology of itgb3 deficient BMM-derived osteoclasts differentiated on bone. (c) Hierarchical clustering heat map of mouse BMM-derived bone
induced osteoclast expression profiles regulated by itgb3.
Table 1 | Comparison of microarray and quantitative RT-PCR expression analysis for selected genes. Wild-type (WT) and integrin beta 3
deficient (Itgb3KO) cells were cultured on plastic or bone substrate withM-CSF and RANKL for 5 days. For each analysis, expression in wild-
type cells (WT) cultured on plastic is set to a value of 1.00, and relative values and standard deviations calculated. Primer sequences are
given in the Methods Section
Microarray Analysis Quantitative RT-PCR
Gene WT Plastic WT Bone Itgb3KO Plastic Itgb3KO Bone WT Plastic WT Bone Itgb3KO Plastic Itgb3KO Bone
AnxA8 (1425789_s_at) 1.00 (0.60) 12.86 (0.80) 0.46 (0.28) 13.33 (1.98) 1.00 (.034) 66.47 (16.98) 1.34 (0.04) 73.96 (19.40)
AnxA8 (1417732_at) 1.00 (0.33) 14.40 (0.80) 0.64 (0.23) 15.88 (1.87)
UCHL1 (1448260_at) 1.00 (0.04) 1.69 (0.06) 0.02 (0.005) 0.04 (0.01) 1.00 (0.13) 2.09 (0.34) 0.02 (0.01) 0.06 (0.03)
FKBP9 (1423677_at) 1.00 (0.08) 1.58 (0.12) 0.19 (0.04) 0.16 (0.04) 1.00 (0.41) 2.91 (1.23) 0.20 (0.09) 0.21 (0.19)
FKBP9
(1437687_x_at)
1.00 (0.02) 1.49 (0.03) 0.15 (0.002) 0.13 (0.01)
SphK1 (1451596_a_at) 1.00 (0.03) 1.52 (0.16) 0.60 (0.06) 0.80 (0.08) 1.00 (0.66) 1.54 (0.48) 0.57 (0.15) 0.83 (0.51)
Spns2 (1451601_a_at) 1.00 (0.09) 1.69 (0.07) 1.62 (0.08) 1.48 (0.21) 1.00 (0.26) 2.39 (0.41) 1.51 (0.70) 1.76 (0.39)
www.nature.com/scientificreports
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(Fig. 4a). Analysis of the microarray data for probes for sphingosine
kinase 1 (SphK1), a key regulator of S-1-P synthesis, revealed robust
induction by RANKL during osteoclast differentiation (day 3–5), with
super-induction by bone substrate most prominent at later stages of
terminal differentiation and activation (day 5) (Fig. 4b), whereas the
related kinase SphK2 was not regulated by RANKL or bone substrate
(not shown). Interestingly, Spns2, a more recently identified S-1-P
transporter29, is regulated in a manner very similar to that of SphK1,
suggesting coordinated regulation of S-1-P synthesis and transport
(Fig. 4b). Pathway analysis revealed that key components of the S-1-P
pathway are regulated by each of the critical determinants of osteo-
clast formation and activation; RANKL, bone and itgb3 (Fig. 4c),
suggesting that this pathway integrates signals emanating from
RANKL signaling, itgb3 engagement, and attachment to bone.
Finally, immunohistochemical analysis of bone erosions in tissue
from a patient with rheumatoid arthritis (RA) revealed strong and
specific SphK1 expression within osteoclasts indicating that the initial
observation of Sphk1 up-regulation in bone adherent osteoclasts
usingmouse cells in culture is directly translated to human osteoclasts
associated with inflammatory bone loss (Fig. 4d). Additionally,
attachment of these osteoclasts to the bone surface further supports
the Sphk1 kinase as a target of regulation by bone.
SphK1 inhibitors negatively regulate osteoclastogenesis. The
preceding results show that the S-1-P pathway is up-regulated in
response to RANKL and also to bone substrate, and that this up-
regulation is dependent, at least in part, by itgb3-mediated interactions
between the differentiating osteoclasts and the bone substrate. To
address the role of EDG pathway induction in osteoclastogenesis,
SphK inhibitors N9,N9 Dimethylsphingosine (N9,N9-DMS) and the
SphK1-selective Compound 5430 were evaluated for effects on in vitro
osteoclast formation from human and mouse precursors.
To assess the potential effects of SphK1 inhibition on osteoclasto-
genesis,mouse BMMwere incubatedwithM-CSF andRANKL in the
presence or absence of different doses of the SphK inhibitors. When
present throughout the 5 days of culture, both inhibitors dose-depen-
dently inhibited generation of tartrate resistant acid phosphatase
(TRAP)-positive multinuclear osteoclasts (Fig. 5a). As expected, loss
of formation of TRAP-positive osteoclasts was reflected in an inhibi-
tion in the formation of resorptive pits when the osteoclasts were
generated on bone slices (Fig. 5b). In addition, induction of express-
ion of osteoclast specific genes was also dose-dependently inhibited
by both of the inhibitors, as illustrated for cathepsin K (Fig. 5c). To
address at which stage of osteoclastogenesis SphK1 activity is
required, osteoclastogenesis assays were performed in which inhibi-
tors were only present during either the first 3 days of culture, or the
final 2 days. Interestingly, inhibition of osteoclastogenesis was seen
in both cases, albeit to a lesser degree than when inhibitors were
present throughout, suggesting that SphK1 inhibition can block
osteoclast formation at multiple stages of differentiation (Fig. 5a).
Finally, the effects of SphK1 inhibitors on human monocyte-derived
osteoclastogenesis were evaluated. As seen for murine cells, these
validated inhibitors showed a dose dependent inhibition of
RANKL-induced formation of TRAP-positive osteoclasts (Fig. 5d)
as well as inhibition of osteoclast gene expression (data not shown).
These results show that SphK1 inhibition potently blocks induction
of osteoclast genes and formation of multinucleated osteoclasts in
both mouse and human in vitro systems.
Taken together, these results show that genes of the S-1-P pathway
are not only co-coordinately regulated by RANKL signaling, itgb3-
mediated attachment, and bone substrate, but also that this pathway
plays a critical role in osteoclastogenesis and activation. In turn, this
validates the profiling studies on the role of bone and itgb3 for the
identification of important pathways regulating osteoclastogenesis
on bone substrates.
Discussion
By definition, functional osteoclasts exist only on bone surfaces, both
in the context of normal bone homeostasis and in inflammatory
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osteolysis, since it is only when associated with bone that these cells
perform their unique and required cellular activity, namely bone
resorption. This observation stresses the importance of considering
the cell culture substrate when analyzing the cellular and molecular
mechanisms regulating osteoclast differentiation and activation in
vitro. To address this need, we have recently demonstrated that
differentiation on bone substrates can profoundly influence osteo-
clast differentiation8,9,11. A wealth of valuable information on the
regulation of osteoclastogenesis has been derived from studies of
osteoclast cells on tissue culture plastic induced by the pro-osteoclas-
togenic cytokines M-CSF and RANKL6,7,31–37. However, little atten-
tion has been paid to this process in the context of bone substrate,
leaving the details of bone regulation of osteoclast gene expression
largely unexplored. This remains an important gap in our knowledge
of osteoclast biology, particularly so because bone regulated osteo-
clast products may represent novel and specific candidate molecules
for therapeutic targeting of the osteoclast. In this paper, we have
addressed this knowledge gap by providing the first comprehensive
characterization on the role of bone substrates on gene expression
during osteoclast differentiation and activation.
Microarray analysis, coupled to qPCR validation and pathway
analysis revealed a number of gene clusters specifically modified by
bone substrate. Focusing on bone regulation of gene sets induced by
RANKL identified coordinated repression by bone during the later
stages of osteoclastogenesis of genes involved in cell cycle progres-
sion and cell division. This would be consistent with a transition
during late osteoclastogenesis from expansion and fusion of the pre-
cursor pool towards polarization and initiation of bone resorption (a
process that can not occur on tissue culture plastic). Although earlier
studies38–40 reported that RANKL can induce downregulation of cell
cycle progression genes during the late stages of osteoclast differenti-
ation, these studies were limited to cells cultured on plastic. Our
results indicate that signaling mediated by bone substrate and itgb3
plays a crucial role in the life cycle of the osteoclast by regulating the
switch from proliferation to terminal differentiation and activation
of bone resorption. It is interesting to note that the bone substrate
mediated repression of expression of genes associated with cell cycle
progression in developing osteoclasts is not seen in macrophages
differentiated in the absence of RANKL. Macrophages, like osteo-
clasts, show a decrease in expression of cell cycle progression genes
during extended culture, likely reflecting a transition to confluency.
Importantly, however, unlike the bone substrate-mediated switch
from osteoclast proliferation to activation, macrophage cell cycle
progression is not further regulated by bone substrate.
In addition to the observed effect on regulation of cell cycle pro-
gression and cell division, bone substrate was also shown to signifi-
cantly regulate the S-1-P pathway responsible for the biosynthesis,
transport and signaling of S-1-P. Moreover, this pathway was inde-
pendently regulated by RANKL signaling, bone substrate and itgb3
mediated attachment of osteoclasts to bone, indicating that multiple
Figure 3 | Regulation of cell cycle progression and proliferation by bone substrate and itgb3. (a) GSEA analysis showing modulation of the cell cycle
progression pathway by both bone and itgb3. (b) Detailed microarray analysis of cdc7 and Cyclin B1 probe sets in cells cultured for 1, 3 and
5 days on plastic or calvaria (bone), in the presence (1RL) or absence (2RL) of RANKL.
www.nature.com/scientificreports
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Figure 4 | Regulation of the S-1-P pathway by RANKL, bone and itgb3. (a) GSEA analysis showing that RANKL, bone and itgb3 each independently
modulates this pathway. (b) Detailed microarray analysis of SphK1 and Spns2 probe sets in cells cultured for 1, 3 and 5 days on plastic or calvaria
(bone), in the presence (1RL) or absence (2RL) of RANKL. (c) Pathway analysis showing S-1-P pathway components that are co-coordinately regulated
by RANKL, itgb3 and bone substrate during osteoclastogenesis. (d) Immunohistochemistry analysis showing SphK1 expression in osteoclasts on the bone
surface in sites of rheumatoid arthritis bone erosions.
www.nature.com/scientificreports
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signals driving osteoclast differentiation converge upon this path-
way. We observe tight coupling between induction of sphingosine
kinase (to generate S-1-P) and the transporter Spns2 (to export
S-1-P), suggesting that upregulation of the S-1-P pathway during
osteoclastogenesis is coupled to increased production and auto-
crine/paracrine signaling by S-1-P. Immunohistochemical analysis
on samples from RA patients confirmed that SphK1 is strongly
expressed in bone resorbing inflammatory osteoclasts in humans.
Importantly, we demonstrated SphK1 inhibitors blocked in vitro
differentiation of mouse and human osteoclasts and expression of
osteoclast associated genes. Consistent with the inhibition of TRAP-
positive osteoclast formation and osteoclast gene expression, SphK1
inhibition also eliminated bone resorption following osteoclast dif-
ferentiation on bone substrate, although further studies are needed to
determine whether this is secondary to differentiation defects, or
indicative of a direct involvement of SphK1 in osteoclast activation.
Such studies will focus on the effects on osteoclast resorptive activity
of inhibiting SphK1 following terminal differentiation on bone sub-
strates. Taken together, these results suggest that the S-1-P pathway
is a critical mediator of osteoclastogenesis that is up-regulated not
only by RANKL signaling, but also during later stages of osteoclast
differentiation by itgb3-mediated attachment to bone.
Sphingosine kinase and S-1-P signaling have previously been
implicated in various aspects of osteoclast biology. Ishii et al23–25 have
demonstrated that interactions between S-1-P and the S-1-P receptor
S1PR1 on osteoclast precursors mediated chemotaxis of these cells to
bone surfaces from the bloodstream, and hence regulate bone home-
ostasis. S1PR1 expression is down-regulated during RANKL-
induced differentiation of osteoclast precursors (a finding confirmed
by our microarray data). However, as previously described by
Pederson et al.27 and validated in the present study, differentiating
osteoclasts greatly amplify their ability to generate S-1-P and hence
potentially recruit additional precursors to the sites of fusion and
osteoclast activation, as well as regulating coupling to bone forma-
tion via interactionwith S-1-P receptors on the surface of osteoblasts.
Our findings that inhibition of SphK1 represses not only generation
of multinucleated osteoclasts but also expression of multiple early
and late osteoclast genes suggests that the role of S-1-P in osteoclas-
togenesis is not limited to recruitment of precursors to fusing osteo-
clasts. This is further supported by the observation that inhibition of
SphK1 during early (pre-fusion) stages of osteoclastogenesis is suf-
ficient to block differentiation. It has been reported that one of the
SphK inhibitors used here (N9,N9-DMS) represses osteoclastogenesis
in a SphK1-independent manner41; however, our observation that
Compound 54, a SphK1-specific inhibitor, blocks osteoclast forma-
tion argues against this. However, themechanism(s) bywhich SphK1
generated S-1-P inhibits osteoclastogenesis remain to be elucidated.
In addition to signaling through cell surface S-1-P receptors, S-1-P
Figure 5 | Inhibition of SphK1 represses RANKL-induced murine and human osteoclastogenesis on plastic and bone. (a) Inhibition of RANKL-
inducedmurine osteoclast formation by Sphk1 inhibitors (N9,N9-DMS and Compound 54) as assessed by quantitation of TRAP-positive multinucleated
cells (n 5 3, * 5 p, 0.05 compared to DMSO control). (b) Pit formation assay showing that the inhibitors (at 2.5 uM) inhibit osteoclast mediated bone
resorption. (c) Effects of SphK1 inhibitors on RANKL-induced expression of Cathepsin K as assessed by quantitative PCR (n5 3, * 5 p, 0.05 compared
to DMSO control). (d) Inhibition of RANKL-induced humanmonocyte-derived osteoclast formation by Sphk1 inhibitors (N9,N9-DMS and Compound
54) as assessed by quantitation of TRAP-positive multinucleated cells (representative experiment of three).
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can act intracellularly, raising the possibility of involvement of mul-
tiple possible paracrine and cell-autonomous mechanisms.
In addition to the above described roles of S-1-P signaling in
RANKL-induced osteoclastogenesis, several lines of evidence point
towards involvement of this pathway in the regulation of TNF sig-
naling. SphK1 deficiency protects mice from TNF-induced arth-
ritis42. Mechanistically, SphK1-generated S-1-P has been shown to
act as a cofactor for TRAF2 downstream of TNF signaling required
for signal transduction from TNFR1 to NF-kB43. Although TNF
alone is insufficient to induce osteoclastogenesis under most condi-
tions, it can potently synergize with low levels of RANKL to drive
osteoclast generation44, and therefore represents a major mediator of
osteoclast mediated bone resorption in inflammatory disease. Thus,
the S-1-P pathway may represent a particularly attractive candidate
for therapeutic targeting of inflammatory osteoclasts.
Taken together, these studies have for the first time characterized
at the molecular level the roles played by bone substrate in the dif-
ferentiation and activation of osteoclasts. Bone regulates numerous
signaling pathways, some but not all of which are dependent upon
itgb3-mediated attachment to the substrate, including cell cycle pro-
gression and the generation, transport and signaling of S-1-P. Since
authentic osteoclasts exist in vivo exclusively on bone, these findings
are critical for a full understanding of osteoclast differentiation and
identification of specific therapeutic targets within resorbing
osteoclasts.
Methods
Differentiation of mouse BMM-derived osteoclasts on different substrates.
Devitalized mouse calvarial bone discs were prepared as described8. M-CSF
dependent BMM were generated from bone marrow cells from 4 individual 6 week
old wild-type mice (C57Bl/6) as described17. Cells were then cultured at a density of
5 3 105 per well in 24 well dishes (Corning Inc., Corning, NY) in the presence of
20 ng/ml mouse M-CSF (R&D Systems, Minneapolis, MN) or mouse M-CSF 1
RANKL (20 ng/ml each) (R&D Systems, Minneapolis, MN) on the devitalized bone
discs, or on tissue culture plastic, or on syntheticHA (Osteologic discs, BDBioscience,
Franklin Lakes, NJ) for 1, 3 and 5 days. Following culture, RNA was extracted using
Trizol, quantitated and assessed for purity, and subjected tomicroarray analysis. Cells
in duplicate wells were fixed with cold 4% paraformaldehyde for 10 minutes for
histological staining.
In a second experiment, M-CSF dependent BMM were generated from bone
marrow cells from 3 wild-type mice (C57Bl/6) and 3 itgb3 deficient12 mice as
described above and cultured at a density of 5 3 105 per well in 24 well dishes
(Corning Inc., Corning, NY) in the presence of mouse M-CSF 1 RANKL (20 ng/ml
each) (R&D Systems, Minneapolis, MN) on devitalized bone discs, or on tissue
culture plastic, for 5 days, prior to RNA extraction andmicroarray analysis or fixation
and staining.
TRAP and actin ring staining. Verification of pre-osteoclasts was confirmed by
staining for tartrate resistant acid phosphatase (TRAP) and actin ring formation in
wild-type and itgb3 deficient osteoclasts was visualized by rhodamine-phalloidin.
TRAP staining was performed using the napthol-based method45. Briefly, cells were
incubated with 0.05 mol/L Acetate buffer, pH 5.0, containing 0.27 mmol/L naphthol
AS-MX phosphate (Sigma-Aldrich, St. Louis, MO), 1% vol/vol N,N-
dimethylformamide, 1.6 mmol/L Fast Red LB salt and 50 mmol/L sodium tartrate at
37uC for 10 minutes.
Following TRAP staining, cells were permeabilized with 0.1% Triton X-100 in PBS
for 3–5 mins. After washing with PBS, cells were incubated with rhodamine-con-
jugated phalloidin solution (Molecular Probes, Carlsbad, CA) diluted 1/200 in PBS
containing 1% BSA for 1 hr. Actin rings were detected by fluorescence microscopy
(Olympus BX-FLA, Osaka).
Microarray experiments and data analysis. One microgram total RNA was used to
synthesize cRNA using the Affymetrix expression protocol (Expression Analysis
Technical Manual; Affymetrix, Santa Clara, CA). Ten micrograms labeled and
fragmented cRNA was hybridized to Affymetrix MOE430.2 chips (Affymetrix, Santa
Clara, CA), and detection signal was calculated using MAS5 algorithm in GCOS
(Expression Analysis Technical Manual; Affymetrix) and sample normalization was
performed using global scaling.
Fold change differences and p-values were calculated using ANOVA, and genes
were considered differentially regulated if they had a fold change of 62 between
groups, and if the false-discovery-rate corrected p-value was ,0.05. Hierarchical
clustering was performed with signal values on differentially-regulated genes, nor-
malized to between 0 and 1 for each gene, and then clustered via Ward’s method.
Pathway analysis was conducted by the Gene Set Enrichment Analysis (GSEA)
method46, using the detection signals as input data, and pathway sets from Biocarta.
Resulting pathways were ranked by FDR q value. Additional functional analysis was
conducted on subsets of the genes using Ingenuity IPA.
Immunohistochemistry. Formalin-fixed, paraffin embedded sections from patients
with inflammatory bone erosions (RA, peri-implant osteolysis) were sectioned and
detected with 15100 (5 mg/ml) rabbit anti-human SphK1 antibody (ab16491, abcam,
Cambridge, MA) or isotype control diluted in PBS. Antigen retrieval was for 7
minutes in 10 mM EDTA pH.7.6 in a scientific microwave, followed by inhibition of
endogenous hydrogen peroxidase with 3% H2O2 in water for 20 minutes at room
temperature and blocking with: 1.5% normal goat serum (Vector Laboratories,
Burlingame, CA) 1 5% FCS for 30 min at room temperature. Secondary antibody
and detection steps were performed using Vector Laboratories kits (Vector
Laboratories, Burlingame, CA) following the manufacturers recommendations.
Sphingosine kinase inhibitors. N, N-Dimethylsphingosine [2S-(dimethylamino)-
4E-octadecene-1,3R-diol; CAS Registry No: 119567-63-4] was purchased from
CaymanChemical (AnnArbor,MI, supplied inDMSO). Compound 54was prepared
as described30 and was solvated in dimethyl sulfoxide (DMSO). Inhibitors were
submitted to Invitrogen/Life Technologies SelectScreen kinase profiling service for
assessing selectivity against lipid kinases (lipid kinase panel) and/or protein kinases
(kinome sampler panel, 50 kinases) at a concentration of 10 mmol/L. Enhanced
selectivity for SphK1 versus SphK2 was confirmed for Compound 54 (100% SphK1
inhibition, with minimal inhibition of SphK2, 18% inhibition). Of protein kinases,
N9,N9-DMS led to 43% inhibition of TRKA and Compound 54 led to 31% inhibition
of FLT3. Neither compound led to substantial inhibition of any other lipid and/or
protein kinase tested (,27% inhibition; data not shown).
In vitro osteoclastogenesis assays in the presence of SphK1 inhibitors. Bone
marrow macrophages (BMM) from C57BL6 mice were isolated by culture of bone
marrow cells for three days on petri dishes in a-MEM medium supplemented with
10% FBS, 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA) and 10%
(equivalent to 140 ng/ml M-CSF) conditioned medium from the M-CSF
overproducing cell line CMG47. Adherent cells were collected by trypsinization and
then cultured in multi-well tissue culture plastic dishes. For osteoclastogenesis, cells
were cultured at 53 104 cells/ml in the samemediumwith GST-RANKL added to 0–
50 ng/ml, in 96-well dishes (200 ml per well) or 24-well dishes (1 ml per well). Where
required, slices of bovine cortical bone were inserted into the wells prior to addition of
cells. Medium was changed after three days. Sphk inhibitors were added at various
doses for either the first 3 days, the last 2 days, or for all five days. DMSOwas added at
equivalent levels to control cultures. Osteoclastogenesis was assessed on day 5 by
TRAP staining (Sigma-Aldrich, St. Louis, MO, kit 386A) followed by counting of
TRAP-positive, multinuclear (3 1 nuclei) cells. Bone resorption was assessed by
removal of cells from bone slices with 2 MNaOH, and incubation for 30minutes with
20 mg/ml peroxidase-conjugated wheat germ agglutinin (Sigma-Aldrich, St. Louis,
MO) followed by 30 minutes with 3,39-diaminobenzidine substrate solution (Vector
Laboratories, Burlingame, CA). For generation of human osteoclasts, CD14-positive
monocytes were prepared from PBMCs derived from de-identified normal human
donors as described previously48. Cells were then cultured at a cell density of 1–2 3
106 cells per milliliter in a-MEM medium (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum (VWR, West Chester, PA) and 1% antibiotic/
antimycotic (Invitrogen, Carlsbad, CA) in the presence or absence of 25 ng/ml
human M-CSF (Peprotech, Rocky Hill, NJ) in 12-well tissue culture plates (1 ml per
well). For osteoclastogenesis, cells were cultured at 3 3 105 cells/ml in the same
medium with GST-RANKL added to 0–40 ng/ml, in 96-well dishes (200 ml per well)
or 24-well dishes (1 ml per well) in the presence or absence of inhibitors.Mediumwas
changed every three days. Osteoclastogenesis was assessed on day 7–9 by TRAP
staining, as described above.
RNA extraction and qPCR. RNA was extracted (RNeasy Mini kit, QIAGEN Inc.,
Valencia, CA) and assessed for concentration and purity by optical density
measurement. 500 ng aliquots of total cellular RNA were reverse transcribed using
oligo-dT primers andMMLV reverse transcriptase (First Strand cDNA Synthesis Kit,
Fermentas) as recommended by the manufacturer. Real time quantitative PCR
(qPCR) was carried out in duplicate using the iCycler iQ thermal cycler detection
system (Bio-Rad Laboratories Inc., Hercules, CA). Reactions included iQTM SYBRH
Green Supermix reagent (Bio-Rad Laboratories Inc., Hercules, CA), 10 ng cDNA,
and forward and reverse primers each at a concentration of 250 nM in a total volume
of 25 ml. mRNA amounts were normalized relative to the house-keeping genes HPRT
or GAPDH, and quantified using the DDCt method49. Generation of only the correct
amplification products was confirmed using melting point curve analysis of the












SCIENTIFIC REPORTS | 4 : 7595 | DOI: 10.1038/srep07595 9




1. Goldring, S. R. & Gravallese, E. M. Pathogenesis of bone erosions in rheumatoid
arthritis. Curr Opin Rheumatol 12, 195–199 (2000).
2. Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504–1508 (2000).
3. Nakashima, T., Hayashi, M. & Takayanagi, H. New insights into osteoclastogenic
signaling mechanisms. Trends Endocrinol Metab 23, 582–590 (2012).
4. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and
activation. Nature 423, 337–342 (2003).
5. Teitelbaum, S. L. & Ross, F. P. Genetic regulation of osteoclast development and
function. Nat Rev Genet 4, 638–649 (2003).
6. Ishida, N. et al. Large scale gene expression analysis of osteoclastogenesis in vitro
and elucidation of NFAT2 as a key regulator. J Biol Chem 277, 41147–41156
(2002).
7. Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1
(NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.
Dev Cell 3, 889–901 (2002).
8. Crotti, T. N. et al. Bone matrix regulates osteoclast differentiation and annexin A8
gene expression. J Cell Physiol 226, 3413–3421 (2011).
9. McHugh, K. et al. Annexin VIII Is a Critical Bone Matrix-dependent Osteoclast
Gene Transcriptionally Regulated by RANKL and NFATc1. Paper presented at:
American Society for Bone and Mineral Research 29th Annual Meeting,
Honolulu, Hawaii, USA. Published by AMER SOC BONE & MINERAL RES,
2025 M ST, NW, Ste 800, Washington, DC 20036-3309 USA, DOI: 10.1002/
jbmr.5650221409, 2007, September 19.
10. McHugh, K. P. et al. Role of cell-matrix interactions in osteoclast differentiation.
Adv Exp Med Biol 602, 107–111 (2007).
11. McHugh, K. P. et al. The role of cell-substrate interaction in regulating osteoclast
activation: potential implications in targeting bone loss in rheumatoid arthritis.
Ann Rheum Dis 69 Suppl 1, i83–85 (2010).
12. McHugh, K. P. et al. Mice lacking beta3 integrins are osteosclerotic because of
dysfunctional osteoclasts. J Clin Invest 105, 433–440 (2000).
13. Ross, F. P. & Teitelbaum, S. L. alphavbeta3 and macrophage colony-stimulating
factor: partners in osteoclast biology. Immunol Rev 208, 88–105 (2005).
14. Zhao, H. et al. Critical role of beta3 integrin in experimental postmenopausal
osteoporosis. J Bone Miner Res 20, 2116–2123 (2005).
15. Bakewell, S. J. et al. Platelet and osteoclast beta3 integrins are critical for bone
metastasis. Proc Natl Acad Sci U S A 100, 14205–14210 (2003).
16. Saltel, F., Destaing, O., Bard, F., Eichert, D. & Jurdic, P. Apatite-mediated actin
dynamics in resorbing osteoclasts. Mol Biol Cell 15, 5231–5241 (2004).
17. McHugh, K. P., Kitazawa, S., Teitelbaum, S. L. & Ross, F. P. Cloning and
characterization of themurine beta(3) integrin gene promoter: identification of an
interleukin-4 responsive element and regulation by STAT-6. J Cell Biochem 81,
320–332 (2001).
18. Izawa, T. et al. c-Src links a RANK/alphavbeta3 integrin complex to the osteoclast
cytoskeleton. Mol Cell Biol 32, 2943–2953 (2012).
19. Morgan, E. A. et al. Dissection of platelet and myeloid cell defects by conditional
targeting of the beta3-integrin subunit. FASEB J 24, 1117–1127 (2010).
20. Nakamura, I., Duong le, T., Rodan, S. B. & Rodan, G. A. Involvement of
alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 25, 337–344
(2007).
21. Nakamura, I., Lipfert, L., Rodan, G. A. & Le, T. D. Convergence of alpha(v)beta(3)
integrin- and macrophage colony stimulating factor-mediated signals on
phospholipase Cgamma in prefusion osteoclasts. J Cell Biol 152, 361–373 (2001).
22. Zhao, H., Ross, F. P. & Teitelbaum, S. L. Unoccupied alpha(v)beta3 integrin
regulates osteoclast apoptosis by transmitting a positive death signal. Mol
Endocrinol 19, 771–780 (2005).
23. Ishii, M. et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and
regulates bone homeostasis. Nature 458, 524–528 (2009).
24. Ishii, M., Kikuta, J., Shimazu, Y., Meier-Schellersheim, M. & Germain, R. N.
Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and
bone remodeling in vivo. J Exp Med 207, 2793–2798 (2010).
25. Ishii, T., Shimazu, Y., Nishiyama, I., Kikuta, J. & Ishii, M. The role of sphingosine
1-phosphate in migration of osteoclast precursors; an application of intravital
two-photon microscopy. Mol Cells 31, 399–403 (2011).
26. Kikuta, J. et al. Sphingosine-1-phosphate-mediated osteoclast precursor
monocyte migration is a critical point of control in antibone-resorptive action of
active vitamin D. Proc Natl Acad Sci U S A 110, 7009–7013 (2013).
27. Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S. & Oursler, M. J. Regulation of
bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine
sphingosine-1-phosphate. Proc Natl Acad Sci U S A 105, 20764–20769 (2008).
28. Ryu, J. et al. Sphingosine 1-phosphate as a regulator of osteoclast differentiation
and osteoclast-osteoblast coupling. EMBO J 25, 5840–5851 (2006).
29. Nishi, T., Kobayashi, N., Hisano, Y., Kawahara, A. & Yamaguchi, A. Molecular
and physiological functions of sphingosine 1-phosphate transporters. Biochim
Biophys Acta 1841, 759–765 (2014).
30. Xiang, Y. et al. Discovery of novel sphingosine kinase-1 inhibitors. Part 2. Bioorg
Med Chem Lett 20, 4550–4554 (2010).
31. Aliprantis, A. O. et al. NFATc1 in mice represses osteoprotegerin during
osteoclastogenesis and dissociates systemic osteopenia from inflammation in
cherubism. J Clin Invest 118, 3775–3789 (2008).
32. de la Rica, L. et al. PU.1 target genes undergo Tet2-coupled demethylation and
DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation.
Genome Biol 14, R99 (2013).
33. Mann, M., Barad, O., Agami, R., Geiger, B. & Hornstein, E. miRNA-based
mechanism for the commitment of multipotent progenitors to a single cellular
fate. Proc Natl Acad Sci U S A 107, 15804–15809 (2010).
34. Miyauchi, Y. et al. The Blimp1-Bcl6 axis is critical to regulate osteoclast
differentiation and bone homeostasis. J Exp Med 207, 751–762 (2010).
35. Mizoguchi, F., Murakami, Y., Saito, T., Miyasaka, N. & Kohsaka, H. miR-31
controls osteoclast formation and bone resorption by targeting RhoA. Arthritis
Res Ther 15, R102 (2013).
36. Sharma, P., Patntirapong, S., Hann, S. & Hauschka, P. V. RANKL-RANK
signaling regulates expression of xenotropic and polytropic virus receptor (XPR1)
in osteoclasts. Biochem Biophys Res Commun 399, 129–132 (2010).
37.Wang, Y., Inger, M., Jiang, H., Tenenbaum, H. &Glogauer, M. CD109 plays a role
in osteoclastogenesis. PLoS One 8, e61213 (2013).
38. Ogasawara, T. et al. Osteoclast differentiation by RANKL requires NF-kappaB-
mediated downregulation of cyclin-dependent kinase 6 (Cdk6). J Bone Miner Res
19, 1128–1136 (2004).
39. Rimondi, E., Zweyer, M., Ricci, E., Fadda, R. & Secchiero, P. Receptor activator of
nuclear factor kappa B ligand (RANKL) modulates the expression of genes
involved in apoptosis and cell cycle in human osteoclasts. Anat Rec (Hoboken)
290, 838–845 (2007).
40. Sankar, U., Patel, K., Rosol, T. J. & Ostrowski, M. C. RANKL coordinates cell cycle
withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase
inhibitors p27KIP1 and p21CIP1. J Bone Miner Res 19, 1339–1348 (2004).
41. Kim, H. J. et al. Suppression of osteoclastogenesis by N,N-dimethyl-D-erythro-
sphingosine: a sphingosine kinase inhibition-independent action.Mol Pharmacol
72, 418–428 (2007).
42. Baker, D. A., Barth, J., Chang, R., Obeid, L. M. & Gilkeson, G. S. Genetic
sphingosine kinase 1 deficiency significantly decreases synovial inflammation and
joint erosions inmurine TNF-alpha-induced arthritis. J Immunol 185, 2570–2579
(2010).
43. Alvarez, S. E. et al. Sphingosine-1-phosphate is a missing cofactor for the E3
ubiquitin ligase TRAF2. Nature 465, 1084–1088 (2010).
44. Lam, J. T. S., Barker, J. E., Kanagawa, O., Ross, F. P. & Teitelbaum, S. L. TNF-alpha
induces osteoclastogenesis by direct stimulation of macrophages exposed to
permissive levels of RANK ligand. J Clin Invest. 106, 1481–1488 (2000).
45. Burstone, M. S. Histochemical demonstration of acid phosphatases with naphthol
AS-phosphates. J Natl Cancer Inst 21, 523–539 (1958).
46. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach
for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102,
15545–15550 (2005).
47. Takeshita, S., Kaji, K. & Kudo, A. Identification and characterization of the new
osteoclast progenitor withmacrophage phenotypes being able to differentiate into
mature osteoclasts. J Bone Miner Res 15, 1477–1488 (2000).
48. Rakshit, D. S. et al. Wear Debris Inhibition of Anti-Osteoclastogenic Signaling by
Interleukin-6 and Interferon-{gamma} Mechanistic Insights and Implications for
Periprosthetic Osteolysis. J Bone Joint Surg Am 88, 788–799 (2006).
49. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25,
402–408 (2001).
Acknowledgments
TC was funded by an American Arthritis Fellowship. We would like to thank Dr. Steven
Brunette for providing SphK1 inhibitor and helpful discussions on inhibitor properties.
Author contributions
E.P. helped conceive the study, performed the inhibitor cell culture and qPCR studies and
wrote the manuscript. T.C. performed the isolation and culture of cells on different
substrates and the actin ring staining experiments as well as RNA isolation and manuscript
feedback. Z.S. performed the immunohistochemistry experiments. J.S. helped conceive the
in vitro inhibitor studies, co-ordinated inhibitor acquisition and characterization and
provided input in writing themanuscript. J.L., J.H., A.H. and J.D. performed themicroarray
experiments and analysis of expression profiles and pathways analysis. G.N. and S.R.G.
helped conceive the study and write the manuscript. K.M. helped conceive the study and
perform the cell culture experiments and RNA extraction of osteoclasts on different
substrates, and wrote the manuscript.
Additional information
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Purdue, P.E. et al. Comprehensive profiling analysis of actively
resorbing osteoclasts identifies critical signaling pathways regulated by bone substrate. Sci.
Rep. 4, 7595; DOI:10.1038/srep07595 (2014).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 7595 | DOI: 10.1038/srep07595 10
This work is licensed under a Creative Commons Attribution-NonCommercial-
NoDerivs 4.0 International License. The images or other third party material in
this article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative
Commons license, users will need to obtain permission from the license holder
in order to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 7595 | DOI: 10.1038/srep07595 11
